proBNP: aging research evidence

MedicinaOct 27

Beyond Cardiorenal Risk Factors: The Prognostic Role of Frailty in Acute Heart Failure

Cohort study of 530 peopleAcute heart failure

Paper

LifeOct 27

Growth Differentiation Factor 15 Is Associated with Severe Coronary Artery Calcification in Patients with Chronic Kidney Disease

Cohort study of 128 peopleCoronary artery calcification

Paper

American Journal of Physiology Heart and Circulatory PhysiologyOct 27

Ovarian Hormone Decline Aggravates Cardiometabolic Risk and Accelerates Heart Failure with Preserved Ejection Fraction in Female ZSF1 Rats

Experiments in 11 ratsMechanisms

Paper

ESC Congress 2026 AbstractOct 26

Higher gut hormone levels linked to cardiovascular events

The highest versus lowest third of hormone levels had a cardiovascular event hazard ratio of 1.79 after accounting for age and sex.The highest versus lowest third of hormone levels had a cardiovascular event hazard ratio of 1.79 after accounting for age and sex.

Cohort · 43,318 peopleCardiovascular disease

Paper

ESC Congress 2026 AbstractOct 26

Heart amyloidosis therapy is linked to lower mortality

Mortality at 24 months was 18% in untreated patients versus 13% in treated patients, with similar benefits in women and men.Mortality at 24 months was 18% in untreated patients versus 13% in treated patients, with similar benefits in women and men.

Cohort · 4,049 peopleInterventions

Paper

ESC Congress 2026 AbstractOct 26

Dapagliflozin did not clearly improve exercise capacity

Peak oxygen use was an adjusted 0.67 milliliters per kilogram per minute lower with dapagliflozin than placebo in stable, symptomatic pulmonary arterial or chronic…Peak oxygen use was an adjusted 0.67 milliliters per kilogram per minute lower with dapagliflozin than placebo in stable, symptomatic pulmonary arterial or chronic thromboembolic pulmonary hypertension.

Randomized trial · 52 peopleDapagliflozin

Paper

ESC Congress 2026 AbstractOct 26

A heart-test model’s false alarms linked to later heart failure

In Alberta’s full test cohort, the model’s false positives had an adjusted hazard ratio of 4.19 for subsequent heart failure versus correct negatives.In Alberta’s full test cohort, the model’s false positives had an adjusted hazard ratio of 4.19 for subsequent heart failure versus correct negatives.

Cohort · 97,631 peopleHeart failure